<DOC>
	<DOCNO>NCT01469819</DOCNO>
	<brief_summary>The purpose study determine lubiprostone may change rate movement food activity stomach intestines subject whose gastrointestinal ( GI ) tract slow due constipation . To able measure time difference duration transit FDA approve SmartPill capsule segment gastrointestinal ( GI ) tract exposure lubiprostone . The investigator anticipate capture possibility reduce/eliminate small intestinal bacterial overgrowth chronically constipate patient administration study drug- lubiprostone .</brief_summary>
	<brief_title>Lubiprostone Effect Gastrointestinal ( GI ) Tract Transit Times Measured Smartpill Patients With Chronic Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>1865 year old At least 6 month history constipation . Constipation define follow : Less three complete spontaneous bowel movement per week one following : 1 . At least 25 % stools hard and/or hard stool 2 . Sensation incomplete evacuation follow least 25 % bowel movement . 3 . Straining least 25 % defecation . The criterion applicable spontaneous bowel movement . Patients spontaneous bowel movement ( bowel movement precede laxative intake ) consider constipate eligible study . For patient â‰¥ 50 year age , normal colonic anatomy document colonoscopy , doublecontrast barium enema , flexible sigmoidoscopy perform within previous 5 year . Pregnancy lactation . Subjects unwilling practice adequate contraception throughout period screen 14 day study termination . Use laxatives 3 day immediately prior randomization ( except fiber bulk agent ) . Use follow drug within 3 day prior randomization : Prokinetic agent ( tegaserod , domperidone , cisapride , metoclopramide , erythromycin ) . Medication contain opiate . Antispasmodic ( e.g. , atropine , hyoscyamine , scopolamine , glycopyrrolate ) . Use illegal drug Regular consumption 2 drink alcohol per day . Chronic nonsteroidal antiinflammatory drug ( NSAIDs ) use Chronic use H2 receptor antagonist proton pump inhibitor ( PPIs ) within 14 day prior screen . History gastric duodenal ulcer , inflammatory bowel disease ( IBD ) , chronic nonulcer dyspepsia . Diabetes Mellitus ( DM ) type 1 , Parkinson 's disease . Existence medical condition require chronic therapy . Positive H. pylorus serology Chronic active diverticulosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>chronic constipation</keyword>
	<keyword>constipation</keyword>
	<keyword>idiopathic constipation</keyword>
	<keyword>SmartPill</keyword>
	<keyword>Wireless Motility Capsule</keyword>
	<keyword>lubiprostone ( Amitiza )</keyword>
	<keyword>small intestinal bacterial overgrowth</keyword>
</DOC>